Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This final session considers a few more populations who might benefit from such a test before the panelists field a final question that speculates what MASEF will look like 2 years from today.
Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This conversation considers applying the test to pediatric populations and the newly classified Met-ALD population (those with MASLD who consume greater amounts of alcohol per week). Additionally, the group considers what’s next for MESAF and how metabolomic tests are becoming commercially available in different countries.
